Rodman & Renshaw initiates Quantum BioPharma coverage with buy rating, US$ 8 target
QNTM•Rodman & Renshaw starts coverage with Buy rating
Rodman & Renshaw initiated coverage of Quantum BioPharma with a Buy rating.
The firm set a US$ 8 price target.
Coverage was described as unpaid, with no consideration provided for the report.
